Charles Ericsson is an Infectious Disease physician. OpenAlex indexes 174 publications with 6,649 citations (h-index 45); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
6410 Fannin St
604
Houston, TX 770303000
Telephone
832-325-7070Registry record last updated 24 May 2026.
Clinical trials
- Single Daily Dose Rifaximin for the Treatment of Travelers' Diarrhea
Sponsor: The University of Texas Health Science Center, Houston
- Azithromycin, With or Without Loperamide, to Treat Travelers' Diarrhea
Sponsor: The University of Texas Health Science Center, Houston
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
3 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Insmed, Inc.Program year20213 payments
- Stryker CorporationProgram year20211 payment
- AbbVie Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
78.5%Macrolide Antimicrobial46.2%Azithromycin100%Part D≥33 patientsShort-acting sulfonamides32.3%Sulfamethoxazole-Trimethoprim100%Part D<11 patientsAntiparasitic
21.5%Antimalarial21.5%Atovaquone-Proguanil Hcl100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Guidelines for the prevention and treatment of travelers’ diarrhea: a graded expert panel report
Journal of Travel Medicine
2017 - Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia
International Journal of Antimicrobial Agents
2015 - Noroviruses as a Cause of Diarrhea in Travelers to Guatemala, India, and Mexico
Journal of Clinical Microbiology
2010 - Prevention of Travelers' Diarrhea With Rifaximin in US Travelers to Mexico
Journal of Travel Medicine
2010
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”